1. Home
  2. HXL vs IMVT Comparison

HXL vs IMVT Comparison

Compare HXL & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hexcel Corporation

HXL

Hexcel Corporation

HOLD

Current Price

$96.87

Market Cap

7.4B

Sector

Industrials

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$38.81

Market Cap

7.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXL
IMVT
Founded
1946
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
7.3B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
HXL
IMVT
Price
$96.87
$38.81
Analyst Decision
Buy
Buy
Analyst Count
10
8
Target Price
$88.30
$33.00
AVG Volume (30 Days)
879.8K
1.5M
Earning Date
04-22-2026
05-28-2026
Dividend Yield
0.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,893,900,000.00
N/A
Revenue This Year
$10.09
N/A
Revenue Next Year
$12.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.20
$14.32
52 Week High
$101.51
$38.90

Technical Indicators

Market Signals
Indicator
HXL
IMVT
Relative Strength Index (RSI) 57.69 72.32
Support Level $81.10 $25.13
Resistance Level $97.69 N/A
Average True Range (ATR) 3.24 1.50
MACD 0.14 0.51
Stochastic Oscillator 65.65 94.14

Price Performance

Historical Comparison
HXL
IMVT

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use primarily in the commercial aerospace and defense markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engine nacelles, and other structures and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: